Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment

Chronic pulmonary infection is the major cause of morbidity and mortality in cystic fibrosis (CF). Recombinant human deoxyribonuclease (rhDNase) in vitro has been shown to dramatically reduce the viscoelasticity of the sputum from CF patients. Phase II and III clinical trials have shown the drug to be safe, and that patients with a forced vital capacity (FVC) of > 40% predicted show an improvement in pulmonary function when receiving rhDNase. The current study evaluates the safety and efficacy of rhDNase in the most severly ill CF patients (FVC < 40% predicted). A double-blind, randomized, placebo-controlled trial in which patients received either 2.5 mg rhDNase twice daily or placebo for a period of 14 days followed by a 6 month open extension period (OEP) is reported. Seventy patients were recruited for the double-blind study, and 64 entered the OEP of whom 38 completed. During the OEP, all patients received 2.5 mg rhDNase twice daily. In both the double-blind period and the OEP the drug appeared to be safe. During the double-blind study, forced expiratory volume in one second (FEV1) and FVC improved in both groups but there was no statistically significant difference between the groups. In the OEP, there was mean improvement in percentage predicted FEV1 and FVC, 9 and 18%, respectively, for all patients participating. In conclusion, DNase is safe when administered in conjunction with a rigorous regimen of chest physiotherapy to severely ill patients (FVC < 40% predicted) with CF. The double-blind, 14 day study showed no significant improvement in pulmonary function but some patients may have improved after longer administration of rhDNase.

This article has been cited by other articles:

				P. A. Flume, B. P. O'Sullivan, K. A. Robinson, C. H. Goss, P. J. Mogayzel Jr., D. B. Willey-Courand, J. Bujan, J. Finder, M. Lester, L. Quittell, et al. Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 957 - 969. [Abstract] [Full Text] [PDF]

				L. J. van der Giessen, R. Gosselink, W. C. J. Hop, and H. A. W. M. Tiddens Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up? Eur. Respir. J., October 1, 2007; 30(4): 763 - 768. [Abstract] [Full Text] [PDF]

				S R Thomas The pulmonary physician in critical care * Illustrative case 1: Cystic fibrosis Thorax, April 1, 2003; 58(4): 357 - 360. [Abstract] [Full Text] [PDF]

				C. A. Robinson and R. J. Kuhn Management of Pulmonary Disease in Patients with Cystic Fibrosis Journal of Pharmacy Practice, June 1, 2001; 14(3): 207 - 227. [Abstract] [PDF]

				J C Davis Jr, S Manzi, C Yarboro, J Rairie, I Mcinnes, D Averthelyi, D Sinicropi, V G Hale, J Balow, H Austin, et al. Recombinant human Dnase I (rhDNase) in patients with lupus nephritis Lupus, January 1, 1999; 8(1): 68 - 76. [Abstract] [PDF]